IL208406A0 - Treatment of brain damage damage using umbilical cord cells - Google Patents

Treatment of brain damage damage using umbilical cord cells

Info

Publication number
IL208406A0
IL208406A0 IL208406A IL20840610A IL208406A0 IL 208406 A0 IL208406 A0 IL 208406A0 IL 208406 A IL208406 A IL 208406A IL 20840610 A IL20840610 A IL 20840610A IL 208406 A0 IL208406 A0 IL 208406A0
Authority
IL
Israel
Prior art keywords
damage
treatment
umbilical cord
cord cells
brain
Prior art date
Application number
IL208406A
Other languages
English (en)
Original Assignee
Stemcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemcyte Inc filed Critical Stemcyte Inc
Publication of IL208406A0 publication Critical patent/IL208406A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL208406A 2008-03-28 2010-10-03 Treatment of brain damage damage using umbilical cord cells IL208406A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7217308P 2008-03-28 2008-03-28
PCT/US2009/001915 WO2009120368A2 (en) 2008-03-28 2009-03-26 Treatment of brain damage using umbilical cord blood cells

Publications (1)

Publication Number Publication Date
IL208406A0 true IL208406A0 (en) 2010-12-30

Family

ID=41114539

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208406A IL208406A0 (en) 2008-03-28 2010-10-03 Treatment of brain damage damage using umbilical cord cells

Country Status (10)

Country Link
US (1) US11318170B2 (https=)
EP (1) EP2282748B1 (https=)
JP (4) JP2011515470A (https=)
CN (1) CN102036671A (https=)
AU (1) AU2009229153B2 (https=)
CA (1) CA2719740C (https=)
IL (1) IL208406A0 (https=)
SG (1) SG191701A1 (https=)
TW (2) TW201636033A (https=)
WO (1) WO2009120368A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
EP2790712B1 (en) * 2011-12-14 2016-08-31 Yeda Research and Development Co. Ltd. Human monocyte sub-population for treatment of central nervous system injury
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
JPWO2015174087A1 (ja) * 2014-05-16 2017-04-20 公益財団法人先端医療振興財団 脳梗塞の予防及び／又は治療の為の医薬
JP7126703B2 (ja) * 2016-05-24 2022-08-29 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
CN108269615A (zh) * 2018-03-14 2018-07-10 南宁市第人民医院 一种脐血pH值与婴幼儿脑损伤的关系评价方法
JP7744897B2 (ja) * 2019-08-20 2025-09-26 ステムサイト インコーポレーテッド 心臓血管疾患の治療

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5087570A (en) 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP1263930A4 (en) 2000-03-09 2004-07-21 Saneron Ccel Therapeutics Inc HUMAN CORD BLOOD BLOOD AS A SOURCE FOR NEURAL TISSUE FOR HEALING THE BRAIN AND BACK MARK
US20010038836A1 (en) * 2000-04-04 2001-11-08 Matthew During Application of myeloid-origin cells to the nervous system
US8062837B2 (en) 2002-02-14 2011-11-22 Stemcyte, Inc. Plasma-depleted, not erythrocyte-depleted, cord blood compositions and method of making
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
DE10330216A1 (de) 2003-07-03 2005-01-20 Jensen, Arne Wilhelm Oluf, Prof. Dr. Verwendung von Stammzellen aus Nabelschnurblut zur Verhinderung von Hirnschäden infolge Sauerstoffmangel und zur Neuroprotektion
US8309070B2 (en) 2004-05-17 2012-11-13 Regents Of The University Of Minnesota Use of umbilical cord blood stem cells to treat ischemic event
US20060264365A1 (en) 2005-05-18 2006-11-23 Hung Li Treatment of brain tissue damage
US7569545B2 (en) 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US7427597B2 (en) 2005-11-21 2008-09-23 Academia Sinica Method of treating brain tissue damages
US8329166B2 (en) 2005-12-16 2012-12-11 Academia Sinica Pluripotent olfactory stem cells
US20100310530A1 (en) 2009-05-21 2010-12-09 Stemcyte Inc. Cell Therapy for Brain Tissue Damage

Also Published As

Publication number Publication date
JP2017031158A (ja) 2017-02-09
EP2282748B1 (en) 2016-11-09
TW200948370A (en) 2009-12-01
EP2282748A2 (en) 2011-02-16
WO2009120368A2 (en) 2009-10-01
JP6655123B2 (ja) 2020-02-26
WO2009120368A3 (en) 2010-01-07
AU2009229153B2 (en) 2015-06-11
JP2014237677A (ja) 2014-12-18
TWI593417B (zh) 2017-08-01
CA2719740A1 (en) 2009-10-01
JP6138090B2 (ja) 2017-05-31
JP2018154634A (ja) 2018-10-04
CA2719740C (en) 2018-11-20
US11318170B2 (en) 2022-05-03
CN102036671A (zh) 2011-04-27
SG191701A1 (en) 2013-07-31
AU2009229153A1 (en) 2009-10-01
TW201636033A (zh) 2016-10-16
JP6401757B2 (ja) 2018-10-10
JP2011515470A (ja) 2011-05-19
US20110256107A1 (en) 2011-10-20
EP2282748A4 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
SI2379087T1 (sl) Celice, izpeljane iz popkovniäśnega tkiva, za zdravljenje nevropatske boleäśine in spastiäśnosti
IL208354A0 (en) Methods of treatment
ZA201008392B (en) Treatment of pluripotent cells
ZA201006070B (en) Methods of treating inflammatory pain
EP2378947A4 (en) METHODS AND DEVICES FOR ENDOSCOPIC ACCESS TO THE HEART
IL217777A0 (en) Methods for treatment of pain
ZA201106730B (en) Methods of treatment using combination therapy
IL214664A0 (en) Methods of treating hair related conditions
GB201104601D0 (en) Water treatment methods
ZA201401706B (en) Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
IL200390A0 (en) Banana treatments
IL208406A0 (en) Treatment of brain damage damage using umbilical cord cells
IL256026B (en) Treatment methods
PL2501381T3 (pl) Leczenie migotania przedsionków
EP2164494A4 (en) Methods of Treatment
GB201204454D0 (en) Methods of inducing tissue regeneration
GB0908101D0 (en) Treatment of stress
GB2482808B (en) Endoscope sheath removal
ZA201005770B (en) The treatment of damaged skin
TWM372020U (en) Holding structure of connector
EP2203432A4 (en) PROCESSING METHOD
GB0700969D0 (en) Methods of treatment
GB0820260D0 (en) Treatment of spinal cord injury
GB0823435D0 (en) Method of treatment
AU2009904460A0 (en) Methods of treatment